Information  X 
Enter a valid email address

Venn Life Sciences (ORPH)

  Print      Mail a friend

Friday 14 June, 2019

Venn Life Sciences

Euronext Growth - Schedule One

RNS Number : 3489C
Venn Life Sciences Holdings PLC
14 June 2019
 

Pre-Admission Announcement
Euronext Growth Schedule 1

Announcement to be made by the Euronext Growth Applicant prior to admission in accordance with rule 2 of the Euronext Growth Rules for Companies

All Applicants must complete the following

Company name  

Venn Life Sciences Holdings plc

 

Company registered address and if different, company trading address (including postcodes)

 

Registered Office:

 

PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ

 

Trading Office:

 

19 Railway Road, Dalkey, Dublin, Ireland

 

Country of incorporation     

England and Wales

Company website address containing all information required by rule 26 in the Euronext Growth Rules for Companies

 

www.vennlifesciences.com/ and with effect from Admission, www.openorphan.com

Company business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 14 of the Euronext Growth Rules for Companies, this should be stated

 

This is a reverse takeover under Rule 14.

 

Open Orphan is Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in France, the Netherlands and Germany.

 

Details of securities to be admitted including any restrictions as to transfer of securities (i.e. where known, number of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

Number of ordinary shares of 0.01 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 253,493,259

 

Placing price per Ordinary Share: 5.6 pence

 

The are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury.

 

     

 

Capital to be raised on admission (if applicable) and anticipated market capitalisation on admission:

 

Capital to be raised on admission: £4.5m (€5.0m)

 

Anticipated market capitalisation on admission: £14.1m (€15.8m)

 

 

 

 

Percentage of Euronext Growth securities not in public hands on admission

 

Approximately 31.1%

 

 

Details of any other exchange or trading platform to which the ex securities (or other securities of the company) are or will be admitted or traded:

 

AIM

 

 

Full names and functions of directors and proposed directors (underlining the first name by which each is known or including any other name by which each is known):

 

Directors:

 

Brendan Buckley, Non-executive Chairman

Cathal Friel, Chief Executive Officer

Christian Milla, Chief Operating Officer

Tony Richardson, Corporate Development Officer

Michael Ryan, Senior non-executive Director

 

Proposed Director:

 

Maurice Treacy, Executive Director

 

 

Full names and holdings of significant shareholders, expressed as a percentage of the issued share capital, before or after admission (underlining the first name by which each is known or including any other name by which each is known):

Before Admission

 

Name

Number of Ordinary Shares

Percentage of issued share capital

Livingbridge VC LLP

13,081,337

18.3%

Kees Groen

4,780,320

6.7%

Calculus

4,696,461

6.6%

 

After Admission

 

Name

Number of Ordinary Shares

Percentage of issued share capital

Cathal Friel

41,046,981

16.2%

Tony Richardson

16,313,388

6.4%

Livingbridge VC LLP

13,081,337

5.2%

Miton Asset Management

8,928,571

3.5%

Crux Asset Management

8,928,571

3.5%

Brendan Buckley

7.845,860

3.1%

 

 

Names of all persons to be disclosed in accordance with schedule two, paragraph (h) of the Euronext Growth Rules for Companies:

n/a

i       anticipated accounting reference date : 31 December

 

ii      date to which the main financial information in the admission document has been prepared:                        31 December 2018

 

 

iii. dates by which it must publish its first three reports pursuant to Rules 18 and 19 in the Euronext Growth Rules for Companies:   30 June 2019 due September 2019, 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020

 

 

Expected admission date

28 June 2019

 

 

Name and address of Euronext Growth Advisor

Davy Corporate Finance, Davy House, 49 Dawson Street, Dublin 2

 

Name and address of broker

 

Arden Partners plc., 125 Old Broad Street, London, EC2N 1AR

Other than in the case of a quoted Applicant, details of where (postal or internet address) the admission document will be available from, with a statement that this will contain full details about the Applicant and the admission of its securities

A copy of the admission document containing full details about the applicant and the admission of its securities will be available on the Company's website, www.vennlifesciences.com

 

Date of notification 

14 June 2019

 

 

 

New/update: New

 

       

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEGGUGGQUPBGGC

a d v e r t i s e m e n t